- Pre-assessment
-
Pre-course assessment
The pre-test is required to access the educational material.
- Review Course Materials
-
Interpreting Cancer Genetic Testing Results
Contains the educational material.
- Post Quiz & Evaluation
-
Post-course assessment
Passing the post-test is required to earn a certificate.
-
Evaluation
-
Accessing your certificate
-
Resources
The resources and references are the same as found in the course material.
-
Tools & resources
Additional resources for more learning about genomic tumor testing
-
More education
-
References
References used to develop the content
Interpreting Cancer Genetic Testing Results (CNE)
Practice interpreting cancer genetic testing results and reports within a patient-specific context.
The results of genetic testing can be complex. While a result may be categorized as positive, negative, or uncertain, the clinical significance of any result depends strongly on the patient’s personal and family history. Whether or not you are the ordering provider, you may be offering additional guidance and coordinating management changes based on the results. In this lesson you will practice interpreting genetic testing results within a patient’s specific context.
To claim credit, follow the steps in the learning path.
CNE Information and Disclosures
Original Release: May 3, 2017
Expiration Date: June 13, 2025
Target Audience
This activity is designed to meet the educational needs of practicing nurses and advanced practice nurses.
Learning Outcome
Identify and manage individuals at increased risk of cancer due to familial factors and hereditary cancer syndromes.
CNE Approval Statement
This nursing continuing professional development activity was approved by the Northeast Multistate Division, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Nurses are eligible for a maximum of .25 contact hours upon the completion of this activity.
Claiming Your Credit
In order to claim credit 1) answer the pre-assessment questions, 2) work through the module content in its entirety, 3) successfully complete the post-assessment answering 2 out of 4 questions correctly and 4) complete the evaluation.
Planners, Writers, and Reviewers
- Emily Edelman, MS, CGC – The Jackson Laboratory
- Therese Ingram, MA – The Jackson Laboratory
- Kalisi Logan, MS, CGC – The Jackson Laboratory
- Kate Reed, MPH, ScM, CGC – The Jackson Laboratory
- Linda Steinmark, MS, CGC – The Jackson Laboratory
- Hayley Dunnack Yackel, PhD, RN, CMSRN, OCN – Hartford Healthcare Cancer Institute
- Fatima Amir, MS, CGC - Genome Medical
Conflict of Interest Disclosure
This educational activity does not include any content that relates to the products and/or services of a commercial interest that would create a conflict of interest. Unless otherwise noted, the program planners and faculty do not have a financial interest/arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this course.
Actors are being used in this program and are presenting information that has been scripted for them. They were not involved with the educational content of this activity. The program does not discuss the off-labeled use of any product.
Commercial Support
An earlier version of this program was supported by educational grants from The Maine Cancer Foundation and The Jackson Laboratory Director's Innovation Fund. There is no commercial support being received for this activity.
References
Bunnell AE, Garby CA, Pearson EJ, Walker SA, Panos LE, Blum JL. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program. J Genet Counsel. 2016; 26(1):105-112.
Desmond A, Kurian AW, Gabree M, et al. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncol. 2015; 1(7):943-.
Easton DF, Pharoah PD, Antoniou AC, et al. Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. N Engl J Med. 2015; 372(23):2243-2257.
Mersch J, Brown N, Pirzadeh-Miller S, et al. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. JAMA. 2018; 320(12):1266-.
National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Detection, Prevention and Risk Reduction. (Requires free registration).
Hardware/Software Requirements
Audio speakers or headphones
Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher
Check the supported browsers.
Should you have technical questions or questions regarding the content of the activity, please email Clinical Education at the Jackson Laboratory.
Disclaimer
All information in Cancer Genetic Clinical Education is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Cancer Genetic Clinical Education. Reliance on any information in Cancer Genetic Clinical Education is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Cancer Genetic Clinical Education.